Question

I am a breastfeeding mother and i want to know if it is safe to use Aflibercept, Ophtalmic use? Is Aflibercept, Ophtalmic use safe for nursing mother and child? Does Aflibercept, Ophtalmic use extracts into breast milk? Does Aflibercept, Ophtalmic use has any long term or short term side effects on infants? Can Aflibercept, Ophtalmic use influence milk supply or can Aflibercept, Ophtalmic use decrease milk supply in lactating mothers?

Aflibercept, Ophtalmic use lactation summary

Aflibercept, Ophtalmic use usage has low risk in breastfeeding
  • DrLact safety Score for Aflibercept, Ophtalmic use is 3 out of 8 which is considered Low Risk as per our analyses.
  • A safety Score of 3 indicates that usage of Aflibercept, Ophtalmic use may cause some minor side effects in breastfed baby.
  • Our study of different scientific research indicates that Aflibercept, Ophtalmic use may cause moderate to no side effects in lactating mother.
  • Most of scientific studies and research papers declaring usage of Aflibercept, Ophtalmic use low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
  • While using Aflibercept, Ophtalmic use We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About Aflibercept, Ophtalmic use usage in lactation

Proteína de fusión recombinante que suprime la neovascularización y disminuye la permeabilidad vascular.Indicada en inyección intravítrea en formas de degeneración y edema maculares y neovascularización coroidea miópica. A fecha de última actualización no encontramos datos publicados sobre su excreción en leche materna. Tras la administración intravítrea las concentraciones plasmáticas a los 1-3 días son bajas (de 0 a 0,05 micorgramos/mL) e indetectables a las 2 semanas. Esa concentración es entre 50 y 500 veces más baja de la necesaria para tener algún efecto sistémico. Además, se une al factor de crecimiento endotelial vascular formando un complejo inerte que, como otras proteínas se degrada por catabolismo protéico. No se acumula tras dosis repetidas cada 4 semanas (EMA 2017). Su elevadísimo peso molecular hacen muy improbable su paso a leche.Por su naturaleza protéica es inactivado en tracto gastrointestinal, no absorbiéndose, por lo que su biodisponibilidad oral es prácticamente nula, salvo en prematuros y periodo neonatal inmediato en los que puede haber mayor permeabilidad intestinal.

Alternate Drugs for Ophthalmologicals-Other agents ATC S01X

Ranibizumab(Safe)
Keracianin(Safe)
Artificial Tears(Safe)
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.